India, April 8 -- Biocon Ltd on Wednesday announced that its subsidiary, Biocon Pharma Ltd, has received approval from the US Food and Drug Administration for its generic version of Dapagliflozin tablets.
The approval covers 5 mg and 10 mg strengths of the drug, which is used to help manage blood sugar levels in adults with Type 2 Diabetes Mellitus.
The medication is indicated as an adjunct to diet and exercise to improve glycemic control. It is also used to reduce the risk of hospitalization due to heart failure in patients with type 2 diabetes who have established cardiovascular disease or multiple risk factors.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....